Abstract 579P
Background
Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in EGFR-mutant non-small cell lung cancer (NSCLC) patients through the phase 3 trial, ARCHER 1050 study. However, there is a lack of real-world data regarding the efficacy of dacomitinib and further sequential treatments after failure of dacomitinib.
Methods
This study included patients with advanced EGFR-mutant NSCLC who received first-line dacomitinib between January 2021 and December 2022 at Samsung Medical Center and St. Vincent Hospital. This study evaluated objective response rate (ORR), progression-free survival (PFS), safety of dacomitinib, and subsequential treatment after failing dacomitinib.
Results
In total, this study included 153 patients, with a median age of 63.7 years. Exon 19 deletion was observed in 50.3%, while the L858R mutation in exon 21 was observed in 46.4% of patients. The ORR was 84.3%. Median follow-up duration was 16.9 months, and the median PFS was 16.7 months (95% CI, 14.4, 25.2). According to type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5, not reached) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5, not reached) in patients with L858R mutation in exon 21. Grade 3 or higher adverse events were observed in 7.2% of patients, with skin rash occurring in 4.6% and diarrhea in 2.0%. Dose reduction of dacomitinib occurred in 85.6% of patients, with a final dose of 30mg in 49.0% and 15mg in 36.6%. Among the 60 patients who experienced disease progression, 32 patients underwent tissue re-biopsy, while among the remaining, 24 patients underwent liquid biopsy. Overall, T790M mutation was detected in 40% of patients who progressed to dacomitinib.
Conclusions
This study highlights the efficacy of dacomitinib as a promising first-line treatment for patients with EGFR-mutant NSCLC in a real-world setting. The detection rate of T790M mutation after dacomitinib treatment failure was similar to that of other 2nd generation EGFR-TKI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Pfizer.
Disclosure
J.E. Shin: Financial Interests, Institutional, Funding: Pfizer.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract